CenterBook Partners LP Raises Stock Position in Merus (NASDAQ:MRUS)

CenterBook Partners LP boosted its position in Merus (NASDAQ:MRUS - Free Report) by 664.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 142,875 shares of the biotechnology company's stock after purchasing an additional 124,174 shares during the quarter. CenterBook Partners LP owned about 0.21% of Merus worth $6,008,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of MRUS. Raymond James Financial Inc. purchased a new stake in shares of Merus in the fourth quarter worth $347,000. Invesco Ltd. increased its stake in Merus by 2.2% in the 4th quarter. Invesco Ltd. now owns 786,365 shares of the biotechnology company's stock worth $33,067,000 after acquiring an additional 16,712 shares during the last quarter. FMR LLC raised its holdings in shares of Merus by 0.4% in the 4th quarter. FMR LLC now owns 6,899,521 shares of the biotechnology company's stock valued at $290,125,000 after acquiring an additional 25,595 shares in the last quarter. Springhill Fund Asset Management HK Co Ltd bought a new stake in shares of Merus during the 4th quarter valued at about $3,524,000. Finally, Wells Fargo & Company MN grew its holdings in shares of Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 300 shares in the last quarter. 96.14% of the stock is owned by institutional investors.

Merus Price Performance

MRUS traded down $0.67 on Monday, hitting $41.30. The company had a trading volume of 137,467 shares, compared to its average volume of 712,377. The stock has a fifty day simple moving average of $43.65 and a 200-day simple moving average of $45.23. The firm has a market capitalization of $2.85 billion, a P/E ratio of -10.46 and a beta of 1.02. Merus has a 52-week low of $33.19 and a 52-week high of $61.61.

Remove Ads

Merus (NASDAQ:MRUS - Get Free Report) last issued its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.48. The business had revenue of $9.14 million during the quarter, compared to analysts' expectations of $10.57 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. Equities research analysts expect that Merus will post -3.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on MRUS. Bank of America dropped their target price on shares of Merus from $73.00 to $70.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Needham & Company LLC reiterated a "buy" rating and issued a $83.00 target price on shares of Merus in a research report on Wednesday, April 9th. Wells Fargo & Company assumed coverage on Merus in a research report on Friday, February 7th. They set an "overweight" rating and a $91.00 price target on the stock. William Blair reiterated an "outperform" rating on shares of Merus in a report on Friday, February 28th. Finally, Guggenheim restated a "buy" rating and issued a $109.00 target price on shares of Merus in a research report on Friday, March 28th. One analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Merus presently has a consensus rating of "Buy" and a consensus price target of $85.31.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.